Regulated AI
AI and data transformation in regulated industries
In healthcare, pharma, biotech, and other research-intensive organizations, an error in how AI and data are governed carries FDA, patient, or scientific consequences. Gabriele Fariello leads the organizational change that makes AI and data create real, governed value in exactly those settings, where rigor and trust are the whole job.
The problem in regulated, high-trust settings
Most AI and data initiatives fail on organizational reality rather than on the technology. In a regulated industry that reality is harder. The work has to satisfy regulators, protect patients, and hold up to expert scrutiny, all while the science and the business keep moving. Data has to be defensible, models and pipelines have to be validated, and every decision has to survive review by people who are paid to be skeptical. The difficulty is rarely the algorithm. It is governance, evidence, and trust under consequence.
That is why a regulated-industry Chief AI Officer or AI-transformation executive needs more than an AI resume. They need someone who has operated where mistakes have real stakes, who can earn the confidence of clinicians, scientists, and regulators, and who can build the teams and the discipline that make governed value repeatable.
How Gabriele approaches it
Gabriele leads the organizational change first and the technology second. He builds the governance, the validated data foundations, and the high-performing teams that let AI and data create value that a regulator or a review board can trust. He is unusually technically deep for a leader at his level and can hold his own with the scientists and engineers he leads, which is what lets him find the path that satisfies the regulator, protects the mission, and still ships. He frames AI-enabled productivity responsibly, as reducing low-value work, redesigning workflows, and creating institutional capacity, done with care.
The proof
The clearest proof is a device Gabriele invented and owns. As Chief Information and Technology Officer of SmartPoints Medical and SmartPoints IoT, he invented and owns the SmartNode, a drop-in appliance that gives a medical or research device a secure, sovereign identity. He took it from concept to a working, tested prototype and validated it at Massachusetts General Hospital on a heavily used research-grade MRI, in research use rather than clinical delivery, securing a high-throughput device without degrading its performance. SmartNode won "Best and Most Novel Data Security Solution" at the 2019 US Business News Technology Elite Awards. This is hands-on, private-sector, regulated-hardware work, not advising on it from the sidelines.
The deeper root is regulated pharmaceutical data. At Millennium Pharmaceuticals, later part of Takeda, Gabriele won FDA and EMA acceptance of a validated statistical data-migration approach in place of a full, slow manual re-entry, helping bring Velcade, a breakthrough cancer therapy, to patients months sooner. He protected the gene-sequence-assembly pipeline that underpinned the company's genomics alliances, publicly reported in the hundreds of millions of dollars per partner, and architected the successor to the company's Sequence Explorer® sequence-analysis software. Getting regulated data right under real regulatory scrutiny is the throughline that runs from that work to the medical device and to every regulated-AI mandate today.
Read the two case studies that carry this focus: the SmartNode secure-identity medical device and regulated pharma data at Millennium/Takeda.
Why it transfers
Across pharma, a major hospital, and a private-sector medical-device venture, the same capability shows up: get regulated data and systems right under scrutiny, earn the trust of expert stakeholders, and build the teams and governance that make it durable. For a regulated-industry CAIO, CIO, or AI-transformation mandate, that record describes someone who creates value where a mistake carries FDA, patient, or scientific consequences, and who has the technical depth to make the AI case believable.